Analyst firms · Morgan Stanley · ACAD
Morgan Stanley ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Morgan Stanley rates ACADIA Pharmaceuticals Inc. (ACAD) Equal-Weight with a $20 price target, as of its latest action on Aug 7, 2024. It has published 5 rating actions on ACAD since August 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Equal-Weight
- Price target
- $20
- Median target, all firms
- $31
- Actions on ACAD
- 5
Morgan Stanley price target on ACAD
Every Morgan Stanley rating on ACAD
- Aug 7, 2024
- Dec 19, 2023
- Dec 7, 2021
- Oct 14, 2021
- Aug 5, 2021
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Morgan Stanley and ACAD
- What is Morgan Stanley's price target for ACAD?
- Morgan Stanley's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $20, from its action on Aug 7, 2024.
- What is Morgan Stanley's rating on ACAD?
- Morgan Stanley rates ACAD Equal-Weight, a neutral rating, as of Aug 7, 2024.
- When did Morgan Stanley last change its view on ACAD?
- On Aug 7, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $28 to $20.
- How does Morgan Stanley's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Morgan Stanley ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.